News

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...
Bariatric surgeon Jonathan Carter discusses the pros and cons of surgery compared with GLP-1 drugs. For those with severe ...
A new virtual health program has helped Grand Strand patients lose more than 2,500 pounds in just six months!Since OrthoSC ...
NYC Health + Hospitals/Lincoln announced on July 10 the launch of a new bariatric surgery program meant to give patients ...
A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.
Thousands of customers are set to receive payments after purchasing a weight loss supplement once described as the “Gastric ...